2-Deoxy adenosine triphosphate improves contraction in human end-stage heart failure.

ABSTRACT: We are developing a novel treatment for heart failure by increasing myocardial 2 deoxy-ATP (dATP). Our studies in rodent models have shown that substitution of dATP for adenosine triphosphate (ATP) as the energy substrate in vitro or elevation of dATP in vivo increases myocardial contraction and that small increases in the native dATP pool of heart muscle are sufficient to improve cardiac function. Here we report, for the first time, the effect of dATP on human adult cardiac muscle contraction. We measured the contractile properties of chemically-demembranated multicellular ventricular wall preparations and isolated myofibrils from human subjects with end-stage heart failure. Isometric force was increased at both saturating and physiologic Ca(2+) concentrations with dATP compared to ATP. T

SUBMITTER: Moussavi-Harami F 

PROVIDER: S-EPMC4301986 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature